Multiparametric MR for Rapid Imaging Assessment of the Liver (RIAL)
Rapid Imaging Assessment of the Liver Using Multiparametric Magnetic Resonance
The RIAL study aims to investigate whether non-invasive measurement of liver fat, iron content and fibrosis are as accurate as liver biopsy specimens in determining if patients have non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), or other suspected liver disease.
Currently, the gold-standard for the diagnosis and staging of liver disease is a liver biopsy.
In this study, consecutive patients will be offered a multiparametric MR scan to assess their liver while they await a liver biopsy.
Study time-frame: The scan will be performed in the 6-week period before their biopsy, and results will be compared to biopsy findings. results will be presented at the end of the study when MR data outcomes are compared to gold-standard biopsy dat. Participants will only have to attend one study visit to participate - there will be no patient follow-up.
調査の概要
詳細な説明
Obesity per se as a cause of liver dysfunction and failure has been well studied. However, although it is a very common disease, at present the only reliable way to diagnose it is with percutaneous liver biopsy. This is painful and not without risk, as the liver is a highly vascular organ. Even with ultrasound guidance, it is still a diagnostic test that is underused as it carries a 1:1000 risk of serious adverse events (eg bleeding, infection, bowel perforation) because it is invasive. Moreover, the patients requiring the test often have impaired clotting of their blood due to liver dysfunction, and so are at higher risk of bleeding, and need to be observed in hospital for a few hours after the procedure. This adds to the cost of the procedure. As a result of these factors, liver biopsy is not used in all patients for whom NAFLD, NASH or other liver disease are suspected, unless the patients have clinically moderate to severe disease.
With the increasing prevalence of obesity in the community, NASH and NAFLD are becoming increasingly common, and there is a need for a reliable, feasible and cost-effective non-invasive diagnostic tool for these conditions. Moreover, they often coexist with other liver diseases (eg tumours, or autoimmune liver disease). There are approximately 1.5million UK adults with mild to moderate liver disease which, at present, cannot be ascertained non-invasively.
Developments in magnetic resonance medicine may allow us to accurately diagnose liver fibrosis, using the amount of extracellular fluid (ECF) as a biomarker for fibrosis. T1 mapping of the liver can reliably show differences in ECF content and thereby allow quantification of the degree of liver fibrosis. In conjunction with MR spectroscopy and T2* mapping for concurrent interpretation of lipid and iron content, this will allow rapid non-invasive diagnosis of the type and/or severity of many common liver diseases (NAFLD/NASH, hepatitis, iron overload).
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
England
-
Oxford、England、イギリス、OX3 9DU
- 募集
- John Radcliffe Hospital, Oxford University Hospitals NHS Trust
-
コンタクト:
- Rajarshi Banerjee, BM BCh MA
- 電話番号:+44 1865 221875
- メール:rajarshi.banerjee@cardiov.ox.ac.uk
-
主任研究者:
- Jane D Collier, MB ChB MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Male or Female over 18 years of age due for diagnostic liver biopsy
- Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria:
- Any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Liver Biopsy patients
All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Liver fat content
時間枠:Day 1
|
Liver fat content in this study is measured with MR spectroscopy during cardiac-gated breatholds
|
Day 1
|
Liver fibrosis
時間枠:Day 1
|
Liver fibrosis is measured by the T1 relaxation time in milliseconds (continuous variable) using MR.
Higher degrees of fibrosis are predicted to have a higher T1 value.
These results will be compared to gold-standard histology.
|
Day 1
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Eleanor Barnes, BSc MBBS PhD、University of Oxford
- スタディディレクター:Stefan Neubauer, MD、University of Oxford
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。